Category: News This Week

  • Smoking Now Viewed as a ‘Moral Offense’

    Smoking Now Viewed as a ‘Moral Offense’

    Vyacheslav Dumchev | Dreamstime.com

    The Freedom Organization for the Right to Enjoy Smoking Tobacco (Forest) released a new report stating that “smoking is no longer seen merely as a health risk to the consumer but as a moral offense to be kept ‘out of sight, out of mind.’”

    The report follows an uptick in smoking and vaping bans across England, Wales and Scotland. Freedom of Information requests were made to 340 authorities in England and Wales and 32 authorities in Scotland; 283 provided responses.

    More than 100 councils banned smoking outside council buildings and on council grounds, and 68 percent of councils had a policy restricting smoking and vaping for employees during working hours. There were 49 councils that banned smoking and vaping breaks completely, even if workers were clocked out, and the bans also included walking between work appointments.

    Many councils, says the report, are introducing outdoor smoking bans by stealth. “This isn’t about the risk of passive smoking, it’s a moral crusade,” said Josie Appleton, author of the report. “Smoking is being treated as a shameful activity that should never be seen in public spaces or near official buildings.”

    Absurdly, according to Forest, some councils are stopping their workers from vaping too, which makes it harder for smokers to give up. “It would be better if councils focused on providing public services rather than interfering in the lifestyle choices of their employees and residents,” Forest wrote in its report.  

  • Menthol Sales up After U.S. Flavor Ban

    Menthol Sales up After U.S. Flavor Ban

    Photo: Photo: Miriam Doerr | Dreamstime.com

    Sales in menthol e-cigarettes have risen since the U.S. Food and Drug Administration (FDA) guidance banning flavors has gone into effect, according to an article in Tobacco Control.

    Since Juul Labs has taken mint flavors off the market and the FDA has banned flavors other than menthol and tobacco, market shares of menthol-flavored e-cigarettes increased.

    After Juul’s actions, there was a 59.4 percent increase in the market share of menthol products after four weeks, and after the FDA guidance, there was a 54.5 percent increase after four weeks and an 82.8 percent increase after eight weeks.

  • Minton: The Double Standard for Nicotine and Cannabis

    Minton: The Double Standard for Nicotine and Cannabis

    The U.S. House of Representatives may soon vote on a historic measure to end federal prohibition on cannabis. Ironically, just as the public and political leaders realize the folly of prohibiting cannabis, we are rushing toward a new prohibition with many of the same pitfalls.

    Prohibiting nicotine vapor is unjustified by all the science so far, which shows health risks are low. Worse, prohibition would prove tragic for smokers, who will be deterred from quitting their deadly habit, Michelle Minton wrote for insidesources.com.

    When e-cigarettes entered the U.S. market in 2007, opponents argued there was limited evidence about product hazards. That implied opponents would relent if and when scientific evidence could establish e-cigarettes’ relative safety. Yet, as evidence mounted, incontrovertibly proving vaporized nicotine was much safer than smoking, efforts to prohibit vaping have only amplified.

    It should have been good news when research literature established nicotine vaping as a more effective for smoking cessation than traditional nicotine replacement therapies. It should have been good news that e-cigarettes didn’t prove a “gateway” for youth smoking that, in fact, youth smoking is at an all-time low.

    MIchelle Minton / Credit: Competitive Enterprise Institute

    And it should have been good news that research failed to link nicotine vaping with significant negative health outcomes, even for those who never smoked. Smokers who switch to vaping actually show rapid improvements in heart and lung health and reduced risk of smoking-related cancers.

    Thus, converting smokers to vapers could save millions of lives.

    But for opponents of e-cigarettes, this evidence isn’t enough. They demand proof that e-cigarettes are 100 percent harmless, an impossible benchmark for any product. The evidence on cannabis is not conclusive, either. For example, there is limited data on how THC impacts cardiovascular health or how cannabis use in adolescence affects future development.

    But that didn’t stop the public and lawmakers from supporting efforts to decriminalize or legalize the drug. Rightly so. Science has a hard time identifying small effects. Thus, after decades of research and centuries of use, of the failure to establish significant harms from cannabis use indicates the harms are marginal.

    That is, cannabis as typically used poses minimal risks for most people, though risks might be greater for certain subgroups or atypical use.

    Conversely, harms caused by prohibition are large and apparent. Not only did prohibition fail to stop people from using cannabis, it spawned a dangerous illicit market, cost billions in enforcement, fomented distrust of law enforcement, devastated communities, and ruined countless lives. Against these costs, concluding that it’s better to give adults access to a legal, regulated market, is obvious.

    That is the conclusion we should have reached for non-combustible nicotine. After more than a decade of intense research, science has yet to link nicotine vaping to any major negative health effects. Many studies claim to have identified potential risks of vaping, but there are an equal or greater number of studies with opposite conclusions.

    What this tells us is the risks of nicotine vaping are likely marginal. And, as with cannabis, there are clear benefits to use of nicotine vapor in terms of health and recreation.

    Conversely, attempts to ban, restrict and heavily tax vapor products have and will continue to inflict a great deal of harm. Banning flavors, restricting sales, and heavily taxing products pushes consumers toward illicit dealers, knockoff products and more dangerous substances. Such policies also drive people back to smoking.

    Yet opposition to these products has grown more extreme and widespread. Contrary to opponents’ rhetoric, their opposition has nothing to do with science and everything to do with morality. Cannabis use is no longer deemed socially unacceptable. But nicotine, thanks to its association with smoking, has only become more stigmatized and no amount of proof will change the minds of those morally opposed to its use.

    Anti-vaping activists will continue to pursue bans and outright prohibition of these products, no matter how safe the science says they are or how many people will die as a result.

    Michelle Minton is a senior fellow with the Competitive Enterprise Institute. She wrote this for InsideSources.com.

  • Legal Marijuana Sales Growing After EVALI Declines

    Legal Marijuana Sales Growing After EVALI Declines

    cannabis vape
    photo: Jeremynathan | Dreamstime

    It was a year ago that lung disease caused by vitamin E acetate in illegal THC pens that caused legal marijuana sales to plummet. Today, marijuana vapor companies report that sales are returning to normal as consumers begin to understand the danger of consuming black market marijuana vape pens.

    Arnaud Dumas de Rauly, co-founder and CEO of New York-based vape manufacturer The Blinc Group, sees this as the biggest impact of the vaping health scare. “It made consumers realize that you can’t just buy any cannabis vaping product,” he said. “You can’t go to the black market.”

    The outbreak of what the Centers for Disease Control and Prevention dubbed e-cigarette or vaping product use-associated lung injury (EVALI) in the summer of 2019 slowed the growth of some companies and stifled sales toward the end of the year, according to a story posted on mjbizdaily.com.

    But vape products, like other cannabis goods, seem to also be weathering not only the health crisis but the current economic downturn. “We’ve seen tremendous bounce back from the vape crisis,” said Sammy Dorf, chief growth officer and co-founder of Verano Holdings, a vertically integrated cannabis company in Chicago. “Business is extremely strong.”

    The COVID-19 pandemic hasn’t slowed business much, either, according to the vape companies, despite fresh warnings that vaping and smoking can make a person more vulnerable to the virus. “We haven’t seen a change in the purchasing pattern of our patients or customers due to the pandemic,” Dorf added.

    How it played out

    The vape health crisis unfolded rapidly, beginning in the summer of 2019 with mainstream media reports seizing on the news that people were dying from allegedly vaping mainly THC products. Some states with regulated cannabis markets such as Washington temporarily banned additives in vapes, while others, including Massachusetts, banned the sale of vape products altogether.

    It took a few months for more information about the illness to surface. Scientists identified one substance, vitamin E acetate, which is added as a cutting agent to some vape oil, as a possible culprit in the lung illness.

    Many industry officials claimed that vitamin E was more commonly found in illicit market products and pointed out that legal cannabis is regulated, tested and safer than unregulated street products.

    Most recently, an academic study published in August confirmed that states lacking licensed, regulated cannabis saw the highest rates of EVALI, particularly those in the northern Midwest. (See chart above.) The report, from the Society for the Study of Addiction, noted “these results suggest that EVALI cases did not arise from e-cigarette or cannabis use per se, but rather from locally distributed e-liquids or additives most prevalent in the affected areas.”

    “We believe the bigger lesson here is that the data clearly indicate that there were fewer cases of lung illnesses and injury in states where legal, regulated cannabis products were available,” said Steve Fox, strategic adviser to the Cannabis Trade Federation. “In fact, the lowest rates of incidence were in Colorado, Washington and Alaska – three of the first four legal states – with Oregon and Nevada close behind.”

    ‘Very scary’

    According to Seattle data-analytics company Headset, sales of adult-use vape products in three of four states with recreational markets generally have recovered, though Nevada retailers saw sales still lower than pre-health scare levels after the state enacted stricter lockdown measures for marijuana retailers during the pandemic.However, market share for vape pens is lower year-over-year, according to the Marijuana Business Factbook, as flower tends to represent a more economical choice amid COVID-19 and greater economic concerns.

    Several cannabis vape business executives interviewed for this story said sales have completely rebounded. George Sadler, president of San Diego-based Platinum Vape, which sells products into several markets, said sales plateaued right after the initial scare but started trending upward in the early winter. “We never really saw much of anything on the level of decline that we thought,” Sadler said.

    Dumas de Rauly said his sales started to recover in December as consumer confidence in the legal market returned. “We have doubled our revenue in terms of vaping hardware since the vaping crisis,” Dumas de Rauly said.

    But he added that his business likely lost a year of growth because of the earlier drop in sales. In Denver, Dan Gardenswartz, chief operating officer at Spherex, said his company’s sales never took a “meaningful hit,” but the end of 2019 was “a little bit of a roller coaster.”

    “It was a very strange time,” he said. “The vape crisis was a very scary thing for people in the industry.”

    Seth Wiggins, chief revenue officer for Clear Cannabis, also in Denver, saw a decline in sales for about 60-90 days before the trend began to reverse. The health crisis “was very painful initially,” he added. However, Wiggins said his company has posted record sales in recent months.

    Illicit to licit

    Wiggins attributes that lift in sales to customers who are shifting from illicit suppliers to legal providers. “The compliant market allows for more regulations and safety,” he added. “It’s breaching the tipping point where the cost basis is not worth the risk” to buy off the street.

    Morgan Fox, spokesman for the National Cannabis Industry Association, also identified that trend. “Across the board, we’ve seen a lot of people moving away from the unregulated market largely because of public-health concerns,” he said.

    Gardenswartz said he saw more people transition from the illicit to the legal market in California than in Colorado, which has imposed tighter controls on illegal dispensaries peddling products. Sadler agreed. He believes there has been some decline in vape sales on the unlicensed market, and he noted that some of his consumers have made the shift from the illicit market to licensed businesses.

    He cited Weedmaps’ decision to curtail advertising for unlicensed dispensaries as helping consumers find legal, tested vape products. Consumers are more aware that they’re going to a licensed dispensary, and stores in California have even displayed QR codes on storefronts so customers know they’re buying from a legal shop.

    “People are more diligent about asking the questions,” he said.

  • Korea to Double Down on E-Liquid Taxes in 2021

    Korea to Double Down on E-Liquid Taxes in 2021

    Credit: Brady Bellini

    The Korean government said Wednesday that taxes on e-liquids will nearly double starting next year. The “health promotion tax” on nicotine solutions will be raised from the current WON525 (0.45 cents) to WON1,050 a milliliter, according to a story in the Korea Herald.

    The changes to the national health promotion laws were approved by the Cabinet recently, according to the Ministry of Health and Welfare, which are set to come into effect Jan. 1, 2021.

    Ministry officials said the revisions are intended to achieve a fairer taxation on varying types of tobacco products. Currently, the tax rate for e-cigarettes is only 43 percent of that for conventional cigarettes.

    The ministry warns against the use of e-cigarettes or vaping products, citing global instances of lung injuries associated with their use. The first local case of a suspected illness linked to vaping was reported in October last year.

  • Australia: Vapor by Prescription Only Starts Mid-2021

    Australia: Vapor by Prescription Only Starts Mid-2021

    Credit: Tom Claes

    Vapor products such as e-cigarettes will become available only by a doctor’s prescription, Australia’s drug regulator said on Wednesday.

    The Therapeutic Goods Administration (TGA) announced its interim decision to reclassify nicotine as a prescription-only medication, meaning nicotine for use in e-cigarettes, and e-juice containing nicotine, would become prescription-only from June 2021, according to the guardian.com.

    The changes would also effect heat-not-burn tobacco products, chewing tobacco, snuff and other novel nicotine products. The decision is open for consultation until Nov. 6.

    Existing state and territory laws make the sale of nicotine e-cigarettes and e-juice illegal throughout Australia and its possession illegal everywhere but in South Australia.

    In a statement, the TGA said the proposed changes meant that “while you would still be able to use the ‘personal importation scheme’ under the Therapeutic Goods Act 1989 to order online from your usual supplier … it would be clear that you would be required to have a prescription”.

    “You would also be able to fill your prescription at your local community pharmacy, however your pharmacy may have to order it in for you,” the statement said.

  • Humble Juice Co. Receives PMTA Acceptance Letter

    Humble Juice Co. Receives PMTA Acceptance Letter

    Humble Juice Co. announced today that the company had received an acceptance letter for its premarket tobacco product application (PMTA) from the U.S. Food and Drug Administration (FDA). Humble submitted its application to the FDA on Sept. 3.

    “Since starting Humble in 2015, we’ve grown more than I could have ever imagined. During that time, we’ve expanded the business while being mindful of future regulation of the e-liquids industry,” said Humble CEO Daniel Clark. “For the past several months, the Humble team has dedicated time and resources to compiling the necessary materials for our PMTA. We are confident in our submission and look forward to providing our customers with flavor-filled, affordable and compliant e-juice long into the future.”

    Humble’s PMTA submission includes product-specific details, consumer survey data, and scientific studies and analyses, as well as risk assessments. Its application specifically pursues marketing orders for 84 e-liquid products in various flavors, nicotine levels and sizes.

    “Our long-term strategy will include the release of additional flavors and nicotine levels,” said Clark. “In the near term, we are focused on working with the FDA to obtain marketing orders for the products submitted in our initial PMTA.”

    Clark added that the Humble team looks forward to the next step in the PMTA journey: the preliminary scientific review of its application.

  • FDA Restates Enforcement Policy for E-Cigarettes

    FDA Restates Enforcement Policy for E-Cigarettes

    Mitch Zeller
    Mitch Zeller, former director of the FDA’s Center for Tobacco Products

    The U.S. Food and Drug Administration (FDA) stated today that it still intends to prioritize enforcement against any electronic nicotine delivery system (ENDS) product that continues to be sold and for which the agency has not received a premarket submission as indicated in FDA’s enforcement priorities guidance.

    “Now that the deadline has passed, and the submissions are with FDA, many may be wondering about the upcoming steps for both submitters and the Agency,” the agency wrote in today’s release. “As Mitch Zeller, CTP Director, stated in a recent perspective piece, FDA strives to be as transparent as possible with regards to the status of these submissions and plans to provide regular updates to the public over the course of the next year.”

    The factors behind enforcing  a device will include several factors, including the likelihood of youth use or initiation. The regulatory agency stated that it will make the best use of agency resources to enforce against any other deemed new tobacco product that does not have the required premarket authorization (PMTA).

    in January of this year, the agency did not mention prioritizing open-systems. The three urgencies that earned a bullet-point were:

    • “Any flavored, cartridge-based ENDS product (other than a tobacco- or menthol-flavored ENDS product);
    • “All other ENDS products for which the manufacturer has failed to take (or is failing to take) adequate measures to prevent minors’ access; and
    • “Any ENDS product that is targeted to minors or whose marketing is likely to promote use of ENDS by minors.”

    “New data, such as that from the 2020 National Youth Tobacco Survey (NYTS), will also inform the FDA’s enforcement and other actions, and flavored disposable ENDS will be an enforcement priority for the agency,” according to today’s agency release.

    The 2020 NYTS showed a large decrease in youth vaping. On Sept. 10, the FDA announced that after two years of disturbing increases in youth e-cigarette use, the agency was “encouraged by the overall significant decline reported in 2020,” the FDA stated in a release. “This is good news; however, the FDA remains very concerned about the 3.6 million U.S. youth who currently use e-cigarettes and we acknowledge there is work that still needs to be done to curb youth use.”

    Complicating matters, while the FDA has said that it plans to post a list of the deemed new tobacco products that were on the market in the U.S. as of Aug. 8, 2016, are still on the market now, and for which a premarket submission was made by Sept. 9, 2020, that list may not be available for many weeks or even months.

    “Before making such a list available, FDA needs to ensure that publishing any such information complies with federal disclosure laws and regulations,” the FDA wrote. “For example, before FDA can include a specific product on this public list, the Agency may need to verify with companies, on a case-by-case basis, the current marketing status of a product and whether it was on the market as of Aug. 8, 2016.”

  • e-LiquiTech to Start Sales of Synthetic (S)- Nicotine

    e-LiquiTech to Start Sales of Synthetic (S)- Nicotine

    Martinmark | Dreamstime.com

    E-liquiTech, a wholly owned subsidiary of Tobacco Technology Inc. (TTI), will start distributing their patented SyNic synthetic (S)- nicotine in November.

    SyNic USP/EP, SyNic nicotine bitartrate and SyNic polacrilex resin are manufactured in U.S. Food and Drug Administration-registered current good manufacturing practices facilities. These products have confirmed purity levels of more than 99.9 percent, (S)- levels of more than 99.7 percent and are free of tobacco-specific nitrosamines and carcinogens.

    “Coupled with e-LiquiTech’s exclusive distribution, competitive pricing and carrying the eLiquiTech guarantee, these products will be available only to responsible partners operating within the regulatory guidelines of the global tobacco industry,” said e-LiquidTech CEO George Cassels- Smith.

    For more information, please send an e-mail to sales@eLiquiTech.com.

  • Hoffmann Webinar on Cannabis Packaging

    Hoffmann Webinar on Cannabis Packaging

    Illustration: Hoffmann Neopac

    Hoffmann Neopac will host a webinar exploring best packaging practices for the burgeoning North American cannabis market. Scheduled for Sept. 29 at 2 pm EST, the hour-long webinar will feature executive-level Hoffmann Neopac presenters well-versed in the cannabis packaging landscape.

    The presentation will feature customer case studies, in which cannabis manufacturers who have partnered with Hoffmann Neopac share insight on differentiating brands in an increasingly competitive marketplace via child-resistant, sustainable packaging solutions.

    Those attending will receive an in-depth overview on the state-by-state U.S. medicinal and recreational regulations, and on business trends for various cannabis formats—including edibles, flowers, pre-rolls, tobacco and creams—on which marijuana is leaving its mark. Presenters will also provide an update on the sector’s strength as it emerges from the Covid-19 pandemic.

    The webinar will also highlight Hoffmann Neopac’s dual packaging specialties—tins and tubes—and how they can be employed to meet child-resistance requirements and sustainability demands while providing exemplary product protection and on-shelf aesthetics.